Mass Spectrometry Imaging of atherosclerosis-affine Gadofluorine following Magnetic Resonance Imaging.
Fabian LohöferRebecca BuchholzAlmut GlinzerKatharina HuberHelena HaasGeorgios KaissisAnnette FeuchtingerMichaela AichlerPeter B SpornsCarsten HöltkeMiriam StöltingFranz SchillingRené M BotnarMelanie A KimmCornelius FaberAxel K WalchAlma ZerneckeUwe KarstMoritz WildgruberPublished in: Scientific reports (2020)
Molecular imaging of atherosclerosis by Magnetic Resonance Imaging (MRI) has been impaired by a lack of validation of the specific substrate responsible for the molecular imaging signal. We therefore aimed to investigate the additive value of mass spectrometry imaging (MSI) of atherosclerosis-affine Gadofluorine P for molecular MRI of atherosclerotic plaques. Atherosclerotic Ldlr-/- mice were investigated by high-field MRI (7 T) at different time points following injection of atherosclerosis-affine Gadofluorine P as well as at different stages of atherosclerosis formation (4, 8, 16 and 20 weeks of HFD). At each imaging time point mice were immediately sacrificed after imaging and aortas were excised for mass spectrometry imaging: Matrix Assisted Laser Desorption Ionization (MALDI) Imaging and Laser Ablation - Inductively Coupled Plasma - Mass Spectrometry (LA-ICP-MS) imaging. Mass spectrometry imaging allowed to visualize the localization and measure the concentration of the MR imaging probe Gadofluorine P in plaque tissue ex vivo with high spatial resolution and thus adds novel and more target specific information to molecular MR imaging of atherosclerosis.
Keyphrases
- mass spectrometry
- high resolution
- magnetic resonance imaging
- contrast enhanced
- cardiovascular disease
- liquid chromatography
- high performance liquid chromatography
- capillary electrophoresis
- metabolic syndrome
- coronary artery disease
- multiple sclerosis
- magnetic resonance
- fluorescence imaging
- insulin resistance
- social media
- health information
- fluorescent probe